Bafna Pharmaceuticals Valuation

Is 532989 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 532989 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 532989 (₹81) is trading above our estimate of fair value (₹1.28)

Significantly Below Fair Value: 532989 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532989?

Key metric: As 532989 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 532989. This is calculated by dividing 532989's market cap by their current revenue.
What is 532989's PS Ratio?
PS Ratio	1.3x
Sales	₹1.43b
Market Cap	₹1.85b

532989 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	32.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 532989's PS Ratio compare to its peers?

The above table shows the PS ratio for 532989 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.7x
ZENITHDRUG Zenith Drugs	1.2x	n/a	₹1.6b
506128 Parnax Lab	1x	n/a	₹2.1b
VAISHALI Vaishali Pharma	2x	n/a	₹2.0b
531726 Panchsheel Organics	2.4x	n/a	₹2.7b
532989 Bafna Pharmaceuticals	1.3x	n/a	₹1.9b

Price-To-Sales vs Peers: 532989 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does 532989's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.4x	n/a	US$86.45m
539561 Remedium Lifecare	0.07x	n/a	US$27.40m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$20.09m
531173 Syschem (India)	0.5x	n/a	US$18.34m

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 532989 is good value based on its Price-To-Sales Ratio (1.3x) compared to the Indian Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 532989's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532989 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 532989's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,196.05

0.8%

-22.8%

Colinz Laboratories

₹141.3m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹56.10

3.0%

37.2%